Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan

Din, Ghufranud; Malik, Sajid; Ali, Ihsan; Ahmed, Safia; Dasti, Javid Iqbal

doi:10.1016/s1995-7645(14)60218-2

Cited by 29 publications

(27 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, our initial results strongly suggest that this group of HCV patients should no longer be regarded as a “difficult” to treat when the new DAAs are used. Our study support the need to make available the DAAs also for south-east Mediterranean and Asian countries considering the large number of patients with haemoglobinopathies and HCV in these areas 41–45…”

Section: Resultssupporting

confidence: 75%

Patients With Haemoglobinopathies and Chronic Hepatitis C: A Really Difficult to Treat Population in 2016?

Zachou

Arvaniti²,

Gatselis³

et al. 2016

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Background & objectivesIn the past, patients with haemoglobinopathies were at high risk of acquiring hepatitis C virus (HCV) due to multiple transfusions before HCV screening. In these patients, the coexistence of haemochromatosis and chronic hepatitis C (CHC) often leads to more severe liver disease. We assessed the HCV prevalence, clinical characteristics and outcome in this setting with particular attention to the response to treatment including therapies with the new direct acting antivirals (DAAs).MethodsThe medical records of 81 consecutive patients followed the last 15 years were reviewed retrospectively.Results43/81 (53%) patients were anti-HCV positive including 31/43 (72.1%) with CHC (HCV-RNA positive; age 25±7 years; 45.2% with genotype 1b; 19.4% cirrhotics; baseline ferritin 887 ng/ml; range: 81–10.820). Thirty patients received IFN-based therapy with or without ribavirin with sustained virological response (SVR) in 14/30 (46.7%). Eleven patients (9 non-responders to IFN-based therapies, one in relapse and one naïve) received treatment with DAAs (SVR: 100%). 3/11 patients increased their transfusion needs while 1/11 reported mild arthralgias. No drug-drug interactions between DAAs and chelation agents were observed as attested by the stability of ferritin levels during treatment.ConclusionsMore than 1/3 of patients with haemoglobinopathies suffered from CHC. Response rates to IFN-based treatment seem to be similar to other patients with CHC, while most importantly, treatment with DAAs was excellent and safe even in difficult to treat patients (most null responders with severe fibrosis) suggesting that this group of HCV patients should no longer be regarded as a difficult to treat.

show abstract

Section: Resultssupporting

confidence: 75%

Patients With Haemoglobinopathies and Chronic Hepatitis C: A Really Difficult to Treat Population in 2016?

Zachou

Arvaniti²,

Gatselis³

et al. 2016

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…As regard thalassemia in the present study, HCV seropositivity prevalence was 30% similar to a study by Din et al in which HCV prevalence in thalassemia was strikingly increased as up to 49% [30], and was also similar to another study done in Iran which reported 15.7% to 63.8% for HCV prevalence in thalassemia [31]. All thalassemia patients in this study were subjected to common risk factors such as blood transfusion, exposure to previous surgery, frequent IV injections and previous hospitalization.…”

Section: Discussion:-supporting

confidence: 91%

Prevalence of hepatitis B and C among some high risk groups in Egyptian children attending Benha University hospital.

Elsherbiny¹,

Abed²,

Mohammed³

et al. 2017

IJAR

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) is a global health problem especially in Egypt. Hepatitis B virus (HBV) is a major cause of chronic liver diseases especially cirrhosis and hepatocellular carcinoma. HBV incidence is markedly reduced after mass vaccination programs application. Objectives: to detect HCV and HBV seroprevalence among some high risk children with molecular confirmation of viremia by real-time PCR for seropositive cases. Materials and methods: A comparative cross sectional study was conducted on 5 groups of Egyptian children attending Benha University Hospital (diabetes mellitus, thalassemia, hemodialysis, previously exposed to surgery and healthy children). All children were subjected to full history taking, physical examination and laboratory investigations including HCV antibodies by 4 th generation ELISA, HBsAg, HBsAb using ELISA, liver function tests and CBC, HCV and HBV viremia detection by real-time PCR for ELISA positive subjects. Results: HCV seropositivity was detected in 5%, 15%, 30%, 50% and 10% for healthy, diabetic, thalassemia, hemodialysis and previously exposed to surgery, respectively. As regard HBV, only a hemodialysis case was positive for both HBsAg and HBV-DNA. Low social class, blood transfusion, frequent intravenous injection, previous surgery and previous hospitalization are major risk factors for HCV transmission. Conclusion:The study revealed high HCV seropositivity prevalence among the studied high risk groups. PCR should be done for all HCV seropositive cases to confirm the presence of viremia.

show abstract

“…Transfusion-transmitted viral infections are a major health problem worldwide, especially in developing countries. Transfusion of blood or its components are often applied as a longterm treatment for patients with thalassemia, hemophilia and chronic renal failure [1][2][3]. Given the increasing use of hepatitis B virus (HBV) vaccine and screening of all donated blood for hepatitis B surface antigen (HBsAg), luckily, the blood transfusionassociated HBV infection rates have dropped dramatically.…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence of Hepatitis B, Hepatitis C and Human Immunodeficiency Virus in Patients with Thalassemia Major in Zahedan, Southeast of Iran

Hoseini

2019

jcbr

View full text Add to dashboard Cite

Background and objectives: Patients with thalassemia are at high risk of hepatitis B, hepatitis C, HIV infections because of the frequent and long-term need for blood transfusion. In the present study, we aimed to determine prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV in patients with thalassemia major in a hospital in Zahedan, Iran. Methods: This descriptive study was performed on 289 thalassemia major patients (130 men and 159 women) who were referred to the Ali ibn Abi Talib hospital in Zahedan, Southeast of Iran. First, serum of patients was checked for presence of antibodies against HB surface antigen, HCV and HIV by ELISA, and then results were confirmed by immunoblotting. Data were analyzed with SPSS 21 software using chi-square test. Results: Of the 289 patients, 11(3.8%) were anti-HBs positive, 11(3.8%) were anti-HCV positive, and none were positive for HIV antibodies. There was no significant difference in the prevalence of the viruses between different age groups. We found no significant correlation between history of HBV vaccination and the absence of infection with the virus in thalassemia patients. Conclusion: Although the prevalence of HCV and HBV infection is not alarmingly high in thalassemia patients in Zahedan (Southeast of Iran), screening of blood donors using more sensitive detection techniques can effectively reduce the prevalence and incidence of these viral infections in this area.

show abstract

Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan

Cited by 29 publications

References 4 publications

Patients With Haemoglobinopathies and Chronic Hepatitis C: A Really Difficult to Treat Population in 2016?

Patients With Haemoglobinopathies and Chronic Hepatitis C: A Really Difficult to Treat Population in 2016?

Prevalence of hepatitis B and C among some high risk groups in Egyptian children attending Benha University hospital.

Seroprevalence of Hepatitis B, Hepatitis C and Human Immunodeficiency Virus in Patients with Thalassemia Major in Zahedan, Southeast of Iran

Contact Info

Product

Resources

About